CUE-102 for Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing a new medicine called CUE-102 that helps the immune system fight cancer more effectively. It targets patients whose cancer hasn't responded to other treatments. The medicine works by activating immune cells to attack cancer cells more precisely.
Research Team
Matteo Levisetti, MD
Principal Investigator
Cue Biopharma
Eligibility Criteria
This trial is for adults (18+) with specific advanced cancers (ovarian, colorectal, stomach, pancreatic) that have worsened despite treatment. Participants must be HLA-A*0201 positive and WT1 positive, have an ECOG performance status of 0 or 1, a life expectancy of at least 12 weeks, measurable disease by CT/MRI scans, and acceptable organ function. They should not be pregnant/breastfeeding and must agree to contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive CUE-102 monotherapy IV infusion every 3 weeks to determine the maximum tolerated dose and establish a recommended Phase 2 dose
Dose Expansion
Participants receive CUE-102 at the recommended Phase 2 dose to expand safety and immune activity data and evaluate antitumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CUE-102
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cue Biopharma
Lead Sponsor